Biotechnology & Medical Research

Page 1

Tigenix to raise capital via private placement of new shares

Wednesday, 25 Nov 2015 02:30am EST

Tigenix NV:Tigenix to raise capital via a private placement of new shares.Launch of a private placement of up to 9,106,180 new shares (5.4 pct of current share capital).Up to 4,149,286 new shares will be offered through an accelerated bookbuilding with institutional investors within European Economic Area.Will issue 4,956,894 new shares to Cormorant Global Healthcare Master Fund, LP at a subscription price of 0.95 euros per share.To use net proceeds of private placement to advance in CX601 marketing authorization approval process in europe and technology transfer of CX601 to Lonza.Has decided to cancel preferential subscription rights of existing shareholders in framework of this transaction.Accelerated bookbuild will start on Nov. 25.

DiaMedica Inc Increases Size of Non-Brokered Private Placement

Tuesday, 24 Nov 2015 11:59am EST

DiaMedica Inc:it has increased the size of the previously announced non- brokered private placement from up to 3,000,000 Units to up to 4,500,000 Units in the capital of the Company at an issue of $0.10 per Unit for gross proceeds of up to $450,000.proceeds will be used by the Company to support development with DM199 for the treatment of vascular diseases and for other working capital purposes.Offering is scheduled to close around November 25th, subject to regulatory approvals.

ATGen announces conversion of fourth convertible bonds

Tuesday, 24 Nov 2015 01:46am EST

ATGen:3,850 mln won worth of its fourth convertible bonds have been converted into 385,000 shares of the company at 10,000 won per share, as of Nov. 24.Listing date of Dec. 11 for the new shares.

Biofrontera raises 3.5 million euros in capital increase

Monday, 23 Nov 2015 10:05am EST

Biofrontera AG:Completes capital increase.Raised net proceeds of 3.5 million euros.

Wilex AG adopts capital measures

Monday, 23 Nov 2015 05:11am EST

Wilex AG:Unveils financing strategy for further development of ADC Technology and adopts capital measures, initially until the end of 2016.Main shareholder Dievini Hopp Biotech Holding GmbH & Co. KG is prepared to invest at least 10 million euros if subscription price does not exceed 1.84 euros per share.To safeguard short-term financing to implement two rights issues using authorised capital without publishing a prospectus, which are expected to generate gross issue proceeds of up to 2.5 million euros for company.Is planning to increase company's share capital by around 10 pct, by issuing 930,560 new no par value bearer shares; issue price per share is 1.84 euros per share.In addition is planning to increase share capital by issuing up to 443,124 new shares at a subscription price of 1.84 euros per share, offered to shareholders for subscription at a 21:1 ratio.Expects to generate issue proceeds of up to 815,348.00 euros from this transaction.

Galectin Therapeutics Inc announces pricing of $9.8 million registered direct offering

Friday, 20 Nov 2015 09:00am EST

Galectin Therapeutics Inc:Has entered into securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,761,900 shares of common stock at a price of $2.06 per share.Offering is expected to close on or about November 25.Net proceeds of the offering, after placement and other fees and estimated expenses payable by Galectin Therapeutics are expected to be approximately $9.1 million.

Theradiag renews standby equity facility with Societe Generale

Friday, 20 Nov 2015 01:00am EST

Theradiag SA:Announces that it has renewed the Standby Equity Facility (SEF) arranged with Societe Generale, as approved by the shareholders' annual meeting of April 16.Société Générale has committed to subscribe to successive capital increases, issued by tranches over the next 24 months, within the global limit of 550,000 shares, reflecting 9.67 percent of the number of shares currently outstanding.

Newron Pharmaceuticals completes 5.4 mln USD/CHF private placement

Thursday, 19 Nov 2015 07:00pm EST

Newron Pharmaceuticals SpA:Completes 5.4 million USD/CHF private placement with U.S. biotechnology/healthcare specialist fund.Subscription price was set at 25.60 Swiss francs per share.

TaiMed Biologics issues new shares

Thursday, 19 Nov 2015 02:32am EST

TaiMed Biologics Inc:Completed to issue 30,000,000 new shares at T$115 per share with amount of T$3,450,000,000 on Nov. 19.New share issue record date Nov. 20.

Quest PharmaTech's Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer

Wednesday, 18 Nov 2015 09:30am EST

Quest PharmaTech:Says its subsidiary, OncoQuest Inc. has closed a U.S.$13,000,000 private placement.This financing is a non-brokered private placement of 3,475,936 Series A preferred shares of OncoQuest at a price of U.S.3.74 per preferred share.preferred shares carry a 5% cumulative annual dividend rate and are convertible one-for-one into common shares of OncoQuest.private placement was made to Hepalink USA Inc. (Hepalink USA), a U.S.-based subsidiary of Shenzhen Hepalink Pharmaceutical Co., Ltd. (Shenzhen Hepalink), a China-based global pharmaceutical company.preferred shares represent a 41% ownership interest in OncoQuest while Quest will retain a 51% ownership interest in OncoQuest.remaining 8% ownership interest in OncoQuest is reserved for various parties from South Korea who gave up their future revenue sharing rights to the Immunotherapy Technologies held under 2 prior Investment Agreements in return for common shares of OncoQuest.OncoQuest plans to use the proceeds of this private placement primarily for its immunotherapy for treatment of cancer drug development program and for general corporate purposes.Under the private placement arrangement, Hepalink USA will also be entitled to nominate two representatives to five member Board of Directors of OncoQuest.Hepalink USA also owns 16.62% of the total outstanding shares of Quest.


  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider : Edison Investment Research
Provider : Edison Investment Research
Provider : Edison Investment Research
Provider : Edison Investment Research
Provider : Edison Investment Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.